Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: Retrospective analysis of the experience of the Fukuoka BMT group

A. Numata, T. Miyamoto, Y. Ohno, T. Kamimura, K. Kamezaki, T. Tanimoto, K. Takase, H. Henzan, K. Kato, K. Takenaka, T. Fukuda, N. Harada, K. Nagafuji, T. Teshima, K. Akashi, M. Harada, T. Eto

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma. To elucidate the role of high-dose chemotherapy (HDCT) with auto-SCT, we retrospectively analyzed the outcomes of 39 patients with PTCL who received HDCT and auto-SCT between 1990 and 2005. Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified. Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients. Thirty-two patients received a pre-transplant conditioning regimen (MCEC) comprising ranimustine, carboplatin, etoposide and CY, and seven did other TBI-based regimens. Rapid engraftment awas obtained in all cases, and transplant-related death was not seen. An estimated 5-year OS was 62.1% with a median follow-up of 78 months. The 5-year OS was significantly higher in patients transplanted during complete response than in those during other disease status (71.4% vs 27.3%, P0.046). HDCT supported by auto-SCT may therefore be effective as consolidation in CR for PTCL treatment.

Original languageEnglish
Pages (from-to)311-316
Number of pages6
JournalBone Marrow Transplantation
Volume45
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

Fingerprint

Peripheral T-Cell Lymphoma
Drug Therapy
Anaplastic Large-Cell Lymphoma
Transplants
Natural Killer T-Cells
T-Cell Lymphoma
Carboplatin
B-Cell Lymphoma
Etoposide
Transplantation

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma : Retrospective analysis of the experience of the Fukuoka BMT group. / Numata, A.; Miyamoto, T.; Ohno, Y.; Kamimura, T.; Kamezaki, K.; Tanimoto, T.; Takase, K.; Henzan, H.; Kato, K.; Takenaka, K.; Fukuda, T.; Harada, N.; Nagafuji, K.; Teshima, T.; Akashi, K.; Harada, M.; Eto, T.

In: Bone Marrow Transplantation, Vol. 45, No. 2, 01.02.2010, p. 311-316.

Research output: Contribution to journalArticle

Numata, A, Miyamoto, T, Ohno, Y, Kamimura, T, Kamezaki, K, Tanimoto, T, Takase, K, Henzan, H, Kato, K, Takenaka, K, Fukuda, T, Harada, N, Nagafuji, K, Teshima, T, Akashi, K, Harada, M & Eto, T 2010, 'Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: Retrospective analysis of the experience of the Fukuoka BMT group', Bone Marrow Transplantation, vol. 45, no. 2, pp. 311-316. https://doi.org/10.1038/bmt.2009.165
Numata, A. ; Miyamoto, T. ; Ohno, Y. ; Kamimura, T. ; Kamezaki, K. ; Tanimoto, T. ; Takase, K. ; Henzan, H. ; Kato, K. ; Takenaka, K. ; Fukuda, T. ; Harada, N. ; Nagafuji, K. ; Teshima, T. ; Akashi, K. ; Harada, M. ; Eto, T. / Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma : Retrospective analysis of the experience of the Fukuoka BMT group. In: Bone Marrow Transplantation. 2010 ; Vol. 45, No. 2. pp. 311-316.
@article{1fced21791594f97a845ce9724c924af,
title = "Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: Retrospective analysis of the experience of the Fukuoka BMT group",
abstract = "Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma. To elucidate the role of high-dose chemotherapy (HDCT) with auto-SCT, we retrospectively analyzed the outcomes of 39 patients with PTCL who received HDCT and auto-SCT between 1990 and 2005. Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified. Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients. Thirty-two patients received a pre-transplant conditioning regimen (MCEC) comprising ranimustine, carboplatin, etoposide and CY, and seven did other TBI-based regimens. Rapid engraftment awas obtained in all cases, and transplant-related death was not seen. An estimated 5-year OS was 62.1{\%} with a median follow-up of 78 months. The 5-year OS was significantly higher in patients transplanted during complete response than in those during other disease status (71.4{\%} vs 27.3{\%}, P0.046). HDCT supported by auto-SCT may therefore be effective as consolidation in CR for PTCL treatment.",
author = "A. Numata and T. Miyamoto and Y. Ohno and T. Kamimura and K. Kamezaki and T. Tanimoto and K. Takase and H. Henzan and K. Kato and K. Takenaka and T. Fukuda and N. Harada and K. Nagafuji and T. Teshima and K. Akashi and M. Harada and T. Eto",
year = "2010",
month = "2",
day = "1",
doi = "10.1038/bmt.2009.165",
language = "English",
volume = "45",
pages = "311--316",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma

T2 - Retrospective analysis of the experience of the Fukuoka BMT group

AU - Numata, A.

AU - Miyamoto, T.

AU - Ohno, Y.

AU - Kamimura, T.

AU - Kamezaki, K.

AU - Tanimoto, T.

AU - Takase, K.

AU - Henzan, H.

AU - Kato, K.

AU - Takenaka, K.

AU - Fukuda, T.

AU - Harada, N.

AU - Nagafuji, K.

AU - Teshima, T.

AU - Akashi, K.

AU - Harada, M.

AU - Eto, T.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma. To elucidate the role of high-dose chemotherapy (HDCT) with auto-SCT, we retrospectively analyzed the outcomes of 39 patients with PTCL who received HDCT and auto-SCT between 1990 and 2005. Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified. Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients. Thirty-two patients received a pre-transplant conditioning regimen (MCEC) comprising ranimustine, carboplatin, etoposide and CY, and seven did other TBI-based regimens. Rapid engraftment awas obtained in all cases, and transplant-related death was not seen. An estimated 5-year OS was 62.1% with a median follow-up of 78 months. The 5-year OS was significantly higher in patients transplanted during complete response than in those during other disease status (71.4% vs 27.3%, P0.046). HDCT supported by auto-SCT may therefore be effective as consolidation in CR for PTCL treatment.

AB - Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma. To elucidate the role of high-dose chemotherapy (HDCT) with auto-SCT, we retrospectively analyzed the outcomes of 39 patients with PTCL who received HDCT and auto-SCT between 1990 and 2005. Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified. Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients. Thirty-two patients received a pre-transplant conditioning regimen (MCEC) comprising ranimustine, carboplatin, etoposide and CY, and seven did other TBI-based regimens. Rapid engraftment awas obtained in all cases, and transplant-related death was not seen. An estimated 5-year OS was 62.1% with a median follow-up of 78 months. The 5-year OS was significantly higher in patients transplanted during complete response than in those during other disease status (71.4% vs 27.3%, P0.046). HDCT supported by auto-SCT may therefore be effective as consolidation in CR for PTCL treatment.

UR - http://www.scopus.com/inward/record.url?scp=76749119337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749119337&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.165

DO - 10.1038/bmt.2009.165

M3 - Article

C2 - 19597416

AN - SCOPUS:76749119337

VL - 45

SP - 311

EP - 316

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -